专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060084654A1 Imidazopyrazine tyrosine kinase inhibitors 有权
标题翻译：咪唑吡嗪酪氨酸激酶抑制剂
公开(公告)号：US20060084654A1
公开(公告)日：2006-04-20
申请号：US10965182
申请日：2004-10-14
申请人： Patricia Beck , Cara Cesario , Matthew Cox , Han-Qing Dong , Kenneth Foreman , Mark Mulvihill , Anthony Nigro , Lydia Saroglou , Arno Steinig , Yingchuan Sun , Qinghua Weng , Douglas Werner , Robin Wilkes , Jonathan Williams
发明人： Patricia Beck , Cara Cesario , Matthew Cox , Han-Qing Dong , Kenneth Foreman , Mark Mulvihill , Anthony Nigro , Lydia Saroglou , Arno Steinig , Yingchuan Sun , Qinghua Weng , Douglas Werner , Robin Wilkes , Jonathan Williams
IPC分类号： A61K31/498 , C07D487/04
CPC分类号： C07D487/04
摘要： Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
摘要翻译：式I化合物及其药学上可接受的盐，其中Q 1和R 1在本文中定义，抑制IGF-1R酶，并且可用于治疗和/或预防通过抑制酪氨酸激酶对治疗作出反应的各种疾病和病症。

2. 发明申请

US20080227788A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS 有权
标题翻译：咪唑吡嗪类激酶激酶抑制剂
公开(公告)号：US20080227788A9
公开(公告)日：2008-09-18
申请号：US10965182
申请日：2004-10-14
申请人： Patricia Beck , Cara Cesario , Matthew Cox , Han-Qing Dong , Kenneth Foreman , Mark Mulvihill , Anthony Nigro , Lydia Saroglou , Arno Steinig , Yingchuan Sun , Qinghua Weng , Douglas Werner , Robin Wilkes , Jonathan Williams
发明人： Patricia Beck , Cara Cesario , Matthew Cox , Han-Qing Dong , Kenneth Foreman , Mark Mulvihill , Anthony Nigro , Lydia Saroglou , Arno Steinig , Yingchuan Sun , Qinghua Weng , Douglas Werner , Robin Wilkes , Jonathan Williams
IPC分类号： A61K31/498 , C07D487/04
CPC分类号： C07D487/04
摘要： Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
摘要翻译：式I化合物及其药学上可接受的盐，其中Q 1和R 1在本文中定义，抑制IGF-1R酶，并且可用于治疗和/或预防通过抑制酪氨酸激酶对治疗作出反应的各种疾病和病症。

3. 发明授权

US07459554B2 Imidazopyrazine tyrosine kinase inhibitors 有权
标题翻译：咪唑吡嗪酪氨酸激酶抑制剂
公开(公告)号：US07459554B2
公开(公告)日：2008-12-02
申请号：US10965182
申请日：2004-10-14
申请人： Han-Qing Dong , Kenneth Foreman , Mark Joseph Mulvihill , Anthony Innocenzo Nigro , Arno G. Steinig , Douglas Werner , Robin Wilkes
发明人： Han-Qing Dong , Kenneth Foreman , Mark Joseph Mulvihill , Anthony Innocenzo Nigro , Arno G. Steinig , Douglas Werner , Robin Wilkes
IPC分类号： C07D413/00 , C07D471/00 , C07D487/00 , C07D491/00 , C07D495/00 , C07D497/00 , C07D415/00
CPC分类号： C07D487/04
摘要： Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
摘要翻译：其中Q1和R1在本文中定义的式和其药学上可接受的盐的化合物抑制IGF-1R酶，并且可用于治疗和/或预防通过抑制酪氨酸激酶对治疗反应的各种疾病和病症。

4. 发明申请

US20060211678A1 Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds 失效
标题翻译：芳基 - 氨基取代的吡咯并嘧啶多激酶抑制化合物
公开(公告)号：US20060211678A1
公开(公告)日：2006-09-21
申请号：US11194158
申请日：2005-08-01
申请人： Saleh Ahmed , Oscar Barba , Jason Bloxham , Graham Dawson , Wiliam Gattrell , John Kitchin , Neil Anthony Pegg , Imaad Saba , Shazia Sadiq , Colin Peter Sambrook Smith , Don Smyth , Amo Steing , Robin Wilkes , Bijoy Panicker , Paula Tavares , Matthew Cox , An-Hu Li , Hanqing Dong , Lifu Ma , Kenneth Foreman , Qinghua Weng , Kathryn Stolz
发明人： Saleh Ahmed , Oscar Barba , Jason Bloxham , Graham Dawson , Wiliam Gattrell , John Kitchin , Neil Anthony Pegg , Imaad Saba , Shazia Sadiq , Colin Peter Sambrook Smith , Don Smyth , Amo Steing , Robin Wilkes , Bijoy Panicker , Paula Tavares , Matthew Cox , An-Hu Li , Hanqing Dong , Lifu Ma , Kenneth Foreman , Qinghua Weng , Kathryn Stolz
IPC分类号： A61K31/5377 , A61K31/519 , A61K31/496 , A61K31/4745 , C07D487/02 , C07D471/02
CPC分类号： C07D471/02 , C07D487/02 , C07D487/04
摘要： Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
摘要翻译：由式（I）表示的化合物或其立体异构体或其药学上可接受的盐是Abl，Aurora-A，Blk，c-Raf，cSRC，Src，PRK2，FGFR3，Flt3，Lck，Mek1，PDK中的至少两种的抑制剂 -1，GSK3beta，EGFR，p70S6K，BMX，SGK，CaMKII，Tie-2，IGF-1R，Ron，Ret和KDR激酶，用于治疗和/或预防各种疾病和病症，癌症。

5. 发明申请

US20060116402A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library 失效
标题翻译： N-取代苯并咪唑c-Kit抑制剂和组合苯并咪唑文库
公开(公告)号：US20060116402A1
公开(公告)日：2006-06-01
申请号：US11290028
申请日：2005-11-30
申请人： Andrew Crew , Matthew Cox , Radoslaw Laufer , Neil Pegg , Colin Sambrook Smith , Yingchuan Sun , Robin Wilkes , Jonathan Williams
发明人： Andrew Crew , Matthew Cox , Radoslaw Laufer , Neil Pegg , Colin Sambrook Smith , Yingchuan Sun , Robin Wilkes , Jonathan Williams
IPC分类号： A61K31/4439 , A61K31/4184 , C07D403/02 , C07D409/02
CPC分类号： C07D235/06 , C07B2200/11 , C07D401/12 , C07D403/10 , C07D403/14 , C07D405/10 , C07D409/10 , C07D409/14 , C07D413/10 , C07D417/14 , C40B40/00
摘要： Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of tumors. Combinatorial libraries composed of compounds represented by Formula (I) or benzimidazole compounds represented by Formula (II): are useful in providing compounds to assay for such therapeutically useful compounds.
摘要翻译：由式（I）表示的化合物或其药学上可接受的盐或N-氧化物可用于治疗肿瘤。由式（I）表示的化合物或由式（II）表示的苯并咪唑化合物组成的组合文库可用于提供化合物以测定这些治疗有用的化合物。

6. 发明授权

US07465726B2 Substituted pyrrolo[2.3-B]pyridines 失效
标题翻译：取代的吡咯并[2,3-B]吡啶
公开(公告)号：US07465726B2
公开(公告)日：2008-12-16
申请号：US11194158
申请日：2005-08-01
申请人： Saleh Ahmed , Oscar Barba , Jason Bloxham , Graham Dawson , William Gattrell , John Kitchin , Neil Anthony Pegg , Imaad Saba , Shazia Sadiq , Colin Peter Sambrook Smith , Don Smyth , Amo G. Steinig , Robin Wilkes , Bijoy Panicker , Paula Tavares , Matthew Cox , An-Hu Li , Hanqing Dong , Lifu Ma , Kenneth (‘Ken’) Foreman , Qinghua (‘Felix’) Weng , Kathryn Stolz
发明人： Saleh Ahmed , Oscar Barba , Jason Bloxham , Graham Dawson , William Gattrell , John Kitchin , Neil Anthony Pegg , Imaad Saba , Shazia Sadiq , Colin Peter Sambrook Smith , Don Smyth , Amo G. Steinig , Robin Wilkes , Bijoy Panicker , Paula Tavares , Matthew Cox , An-Hu Li , Hanqing Dong , Lifu Ma , Kenneth (‘Ken’) Foreman , Qinghua (‘Felix’) Weng , Kathryn Stolz
IPC分类号： A61K31/437 , A61K31/496 , A61K31/5355 , A61K31/541 , A61K31/5513 , A61K31/551 , C07D471/04 , C07D223/04 , C07D243/08 , C07D241/04 , C07D413/10 , C07D413/06 , C07D413/08 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/14 , A61K31/04 , A61K31/519 , C07D487/04
CPC分类号： C07D471/02 , C07D487/02 , C07D487/04
摘要： Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
摘要翻译：由式（I）表示的化合物或其立体异构体或其药学上可接受的盐是Abl，Aurora-A，Blk，c-Raf，cSRC，Src，PRK2，FGFR3，Flt3，Lck，Mek1，PDK中的至少两种的抑制剂 -1，GSK3beta，EGFR，p70S6K，BMX，SGK，CaMKII，Tie-2，IGF-1R，Ron，Ret和KDR激酶，用于治疗和/或预防各种疾病和病症，癌症。

7. 发明申请

US20100290962A1 FUNCTIONALISED MATERIALS AND USES THEREOF 审中-公开
标题翻译：功能材料及其用途
公开(公告)号：US20100290962A1
公开(公告)日：2010-11-18
申请号：US12738743
申请日：2008-10-20
申请人： John Robert Howe Wilson , Nico Galaffu , Siud Pui Man , Robin Wilkes
发明人： John Robert Howe Wilson , Nico Galaffu , Siud Pui Man , Robin Wilkes
IPC分类号： C22B11/00 , B01J41/12 , C02F1/42 , C22B23/00
CPC分类号： C07F7/21 , A61K47/24 , A61K47/34
摘要： [(O3/2)SiCH2CH2SX]a[Si(O4/2)]b[WSi(O3/2)]c[VSi(O3/2)]d wherein X is selected from (CR1R2)eNR5CO NHR, (CR1R2)eNR5CSNHR, W when present is selected from (CR6R7)eZR, (CH2)3SR1(CH2)3NRR1, (CH2)eSR8, CH2CH2S (CR1R2)fNR5CONHR, CH2CH2S(CR1R2),NR5CSNHR, CH2CH2S(CH2)fOR; Z is O or S, R, R1-7 are independently selected from hydrogen, alkyl group, aryl group or alkylaryl group, R8 is selected from [CH2CH2NR1]PR and (CR1R2)mSR9 where R9 is hydrogen, C1-22-alkyl group, and V is a group which is optionally substituted and selected from a C1-22-alkyl group, C2-22-alkenyl group, a C2-22-alkynyl group or an aryl group. The compounds are useful as immobilisation materials for bio-molecules including enzymes, cation and anion exchangers, organic and inorganic compound scavengers, solid phase purification or extraction materials, removal and purification of biological compounds including endotoxins, anti-microbial agents, hydrophilicity modifiers, flame proofing agents, antistatic agents, coatings for biomedical devices, water repellent films and coatings, solid phase synthesis materials and chromatography materials.
摘要翻译： [（O3 / 2）SiCH2CH2SX] a [Si（O4 / 2）] b [WSi（O3 / 2）] c [VSi（O3 / 2）] d其中X选自（CR1R2）eNR5CO NHR，（CR1R2）当存在时，eNR5CSNHR，W选自（CR6R7）eZR，（CH2）3SR1（CH2）3NRR1，（CH2）eSR8，CH2CH2S（CR1R2）fNR5CONHR，CH2CH2S（CR1R2），NR5CSNHR，CH2CH2S（CH2）fOR; Z为O或S，R 1，R 7为独立地选自氢，烷基，芳基或烷基芳基，R 8选自[CH 2 CH 2 NR1] PR和（CR 1 R 2）m S R 9，其中R 9为氢，并且V是任选被取代并选自C 1-22烷基，C 2-20 - 烯基，C 2--22 - 炔基或芳基的基团。该化合物可用作包括酶，阳离子和阴离子交换剂，有机和无机化合物清除剂，固相纯化或提取物质在内的生物分子的固定物质，除去和纯化包括内毒素，抗微生物剂，亲水性改性剂，火焰防静电剂，生物医学装置用涂料，防水膜和涂料，固相合成材料和色谱材料。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式